Obstetrics & Gynecology Ultrasound Devices Market By Technology (2D Ultrasound, 3D & 4D Ultrasound, Doppler Ultrasound); By Portability (Cart-Based, Handheld); By Application (Obstetrics, Gynecology); By End-User (Hospitals, Clinics, Fertility Centers, ASCs); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Obstetrics & Gynecology Ultrasound Devices Market: Advancing Women’s Diagnostic Imaging Through AI Innovation, Portable Systems, and Rising Prenatal Care Demand

The Global Obstetrics & Gynecology Ultrasound Devices Market was valued at USD 4.15 billion in 2025 and is projected to reach USD 6.75 billion by 2032, expanding at a CAGR of 7.2% during 2026–2032, according to Strategic Market Research. 

 

Obstetrics and gynecology ultrasound devices are used to monitor fetal development and diagnose reproductive and women’s-health conditions. By system type, the market includes cart-based, portable/laptop, and handheld/wireless systems. Cart-based platforms provide advanced, full-featured imaging for hospitals and specialist clinics, while portable systems combine mobility with broad diagnostic capabilities. Handheld devices support rapid bedside, outpatient, and point-of-care examinations. Imaging capabilities include 2D, 3D/4D, Doppler, and elastography. Standard 2D ultrasound is widely used for fetal and organ assessment, 3D/4D imaging provides more detailed fetal visualization, Doppler evaluates blood flow, and elastography assesses tissue stiffness in certain gynecologic conditions. Transabdominal probes support deeper fetal and pelvic imaging, whereas transvaginal probes provide high-resolution visualization during early pregnancy and detailed examination of the uterus and ovaries.

 

Pregnancy remains the largest recurring imaging base for the market, while fertility treatment, early pregnancy assessment, uterine fibroids, endometriosis, polycystic ovary syndrome (PCOS), ovarian abnormalities, and abnormal bleeding broaden demand across women’s healthcare. Obstetric ultrasound is routinely used for pregnancy dating, fetal anatomy assessment, growth monitoring, and management of high-risk pregnancies. In the United States, more than 12 million obstetric ultrasound examinations are performed annually, and an average pregnancy may involve approximately four to five scans, particularly when additional monitoring is required for maternal or fetal complications.

 

Globally, utilization is also substantial. Major medical technology companies estimate that installed ultrasound systems support approximately 170 million obstetric and gynecological procedures worldwide each year, highlighting the large recurring demand for imaging across maternal and women’s healthcare. The United States recorded 3,628,934 live births in 2024, while the UN World Population Prospects dataset indicates approximately 132.4 million births globally in 2025. In addition, WHO recommends an ultrasound examination before 24 weeks of pregnancy as part of antenatal care. These patient volumes create a broad and recurring foundation for obstetric imaging, while high-risk pregnancies and fertility treatments can require multiple examinations within a single care pathway.

 

Access to ultrasound services, however, remains uneven. Urban areas and well-equipped healthcare centers generally have higher utilization, whereas rural communities can face limited availability because of fewer imaging facilities, shortages of trained professionals, and hospital or maternity-unit closures. These disparities are increasing the need for portable, handheld, and efficient ultrasound technologies that can extend prenatal and gynecologic imaging beyond major hospitals and specialist centers.

 

Growth through 2032 is expected to be supported by increasing high-risk pregnancy monitoring, expansion of fertility services, rising use of gynecologic imaging, replacement of aging ultrasound equipment, and greater adoption of automated and portable platforms. Mature healthcare markets are increasingly focused on productivity improvements, workflow efficiency, equipment upgrades, and advanced imaging capabilities, while developing healthcare systems continue to expand basic access to maternal and women’s-health diagnostic services.

 

Technology development is becoming another important source of market expansion. A major trend across both portable and cart-based systems is the integration of artificial intelligence, particularly for automated fetal biometry, measurement assistance, anomaly detection, tissue analysis, image optimization, and streamlined reporting. These capabilities can reduce repetitive manual tasks, improve consistency, and support faster clinical workflows. At the same time, smaller and wireless platforms are expanding point-of-care applications in clinics, community settings, and locations where conventional cart-based systems may be less practical.

 

Recent FDA approvals and clearances in OB/GYN ultrasound increasingly reflect this movement toward portability, AI integration, specialized fertility applications, and remote diagnostic use. Examples include FemVue Controlled for non-radiation, in-office tubal infertility testing; GE HealthCare’s AI-enabled LOGIQ and Vscan Air systems; and Pulsenmore’s at-home fetal ultrasound device, which supports remote pregnancy monitoring. These developments demonstrate how ultrasound technology is moving beyond conventional hospital-based imaging toward more decentralized and connected models of care.

 

Handheld systems such as GE Vscan Air, Philips Lumify, and Healcerion SONON 300C are FDA-cleared for routine obstetric and pelvic imaging, supporting point-of-care examinations outside traditional hospital imaging departments. Specialized solutions such as FemVue Controlled enable contrast-enhanced, radiation-free assessment of fallopian tube patency during infertility evaluation. Meanwhile, major cart-based platforms from GE HealthCare, Samsung Medison, Canon Medical, and Esaote increasingly incorporate AI-supported functions, including automated fetal measurements and enhanced tissue analysis, to improve diagnostic accuracy and clinical workflow.

 

Another emerging area is home-based and remotely supported ultrasound. Solutions such as Pulsenmore are introducing models in which fetal imaging can be performed outside conventional clinical environments and incorporated into telehealth-supported prenatal care. Although hospital and specialist imaging will remain central to complex diagnosis, remote and portable ultrasound technologies could improve access for selected patients, particularly where travel distance, provider shortages, or limited imaging infrastructure restrict regular prenatal monitoring.

 

Overall, the market is evolving from a predominantly hospital-centered imaging segment toward a broader ecosystem combining advanced cart-based systems, portable platforms, handheld ultrasound, AI-assisted imaging, specialized fertility applications, and remote monitoring technologies. The large recurring pregnancy population, expanding fertility and gynecologic imaging needs, replacement of older systems, growing emphasis on high-risk pregnancy surveillance, and continued improvements in portability and automation are expected to support sustained market growth through 2032.

 

Higher-Risk Pregnancy Care Is Raising Imaging Demand

High-Risk Pregnancy and Advanced Obstetric Imaging Demand

High-risk and complicated pregnancies often require repeated maternal and fetal assessment, increasing the need for reliable imaging, faster examinations, accurate measurements, and consistent monitoring across hospitals and maternal-fetal-medicine practices. High-risk pregnancies can involve maternal medical conditions, multiple gestation, pregnancy-related disorders, fetal abnormalities, or other factors that require closer clinical surveillance.

Approximately 6% to 8% of pregnancies in the United States are estimated to be high-risk. Applied to the 3,628,934 U.S. live births recorded in 2024, this percentage indicates a substantially larger potential monitoring population than 30,000–65,000 cases and would correspond to roughly 218,000–290,000 births if live births are used as a simple reference base. Published research also estimates that approximately 20 million pregnancies globally are classified as high-risk, creating a significant patient population that may require more frequent fetal growth assessment, placental evaluation, Doppler studies, and other ultrasound-based surveillance.

The broader burden of maternal complications further reinforces the importance of effective antenatal assessment. The United States recorded 649 maternal deaths in 2024, equivalent to 17.9 deaths per 100,000 live births, while WHO estimates that approximately 260,000 women died from maternal causes worldwide in 2023. These mortality figures are not direct measures of ultrasound utilization, but they demonstrate the continuing clinical burden surrounding pregnancy and childbirth. Ultrasound contributes to antenatal evaluation by helping clinicians assess fetal growth, gestational age, placental position, multiple pregnancies, fetal presentation, and other conditions that may affect monitoring or referral decisions.

Hospital-based obstetric activity also creates substantial imaging demand. The United States recorded 1,173,391 cesarean deliveries in 2024, representing 32.4% of all deliveries. Not every cesarean delivery represents a high-risk pregnancy, but the large procedure volume illustrates the scale of pregnancies managed in hospital settings where ultrasound can support assessment of fetal presentation, placental location, fetal growth, and pregnancy progression before delivery.

Together, the substantial population of high-risk pregnancies, repeated monitoring requirements, maternal complications, and large hospital delivery volumes supports continued demand for obstetric ultrasound equipment. Maternal-fetal-medicine departments and tertiary hospitals require advanced systems capable of detailed fetal imaging and Doppler assessment, while routine obstetric practices increasingly benefit from mid-range and portable platforms that enable efficient follow-up examinations and broader access to prenatal imaging.

 

Gynecologic Disorders Expand Demand Beyond Pregnancy

Gynecologic imaging provides a large non-pregnancy demand base. Endometriosis, PCOS, uterine fibroids, ovarian cysts and other pelvic abnormalities generate ultrasound use across diagnosis, treatment planning and follow-up.

WHO estimates that endometriosis affects around 190 million reproductive-age women globally. PCOS affects an estimated 10–13% of reproductive-age women worldwide, with a considerable portion remaining undiagnosed. In the United States, 2022–2023 data show that 6.2% of women ages 20–49 reported an endometriosis diagnosis, 8.7% reported PCOS and 7.8% reported uterine fibroids.

Fibroids are particularly relevant because ultrasound can support diagnosis, treatment planning and follow-up. A global epidemiological analysis estimated approximately 226 million prevalent uterine-fibroid cases in 2019. Ovarian and adnexal abnormalities add another important use, particularly when clinicians need to characterize masses or monitor selected cysts.

These conditions broaden demand beyond maternity departments and create regular imaging volumes for gynecology practices, hospitals and diagnostic centers.

 

AI and Automation Are Reshaping Product Competition

Recent supplier activity shows that product development is increasingly centered on workflow efficiency, automated measurements and broader women’s-health coverage.

GE HealthCare received FDA 510(k) clearance in 2025 for updated Voluson Expert 22, 20 and 18 systems. The portfolio incorporates automated image recognition, annotation and measurement capabilities for obstetric, pelvic-floor and fertility examinations.

Samsung Medison expanded similar capabilities in its HERA Z20 platform, including automated extraction of ultrasound views and measurements during pregnancy examinations. Siemens Healthineers offers automated obstetric biometric measurements and Auto Follicle capabilities for fertility assessment, while Philips continues to extend OB/GYN imaging into handheld systems.

Canon Medical and Mindray also maintain dedicated women’s-health ultrasound portfolios. Current development activity across these companies shows that competition is moving beyond image quality toward productivity, standardized measurements, reporting efficiency and broader clinical coverage.

 

Portable Ultrasound Is Extending Imaging Beyond Traditional Departments

Cart-based systems remain important in hospitals, specialist OB/GYN practices and maternal-fetal-medicine centers, particularly for complex examinations. Handheld systems are expanding the range of settings in which ultrasound can be delivered.

Philips' Lumify platform, for example, supports fetal, obstetric, gynecologic and transvaginal applications. Portable systems can fit outpatient clinics, bedside imaging and facilities where space or capital budgets make full-size systems less practical. They can also serve as supplementary systems in larger hospitals.

This creates two complementary equipment opportunities. High-end cart-based platforms remain important for complex fetal and gynecologic imaging, while handheld systems expand availability across smaller practices and decentralized care. Market growth therefore comes from both replacement of premium platforms and wider adoption of portable devices.

 

Obstetrics & Gynecology Ultrasound Devices Market Segmentation and Revenue Forecast

By Technology

Based on Strategic Market Research segment revenue estimates, 2D ultrasound accounted for approximately 44.0% of the market in 2025, representing around USD 1.83 billion, making it the largest technology segment. Its broad use in routine pregnancy and general gynecologic examinations supports continued demand. The segment is projected to grow at approximately 6.0% CAGR, reaching around USD 2.75 billion by 2032.

3D & 4D ultrasound represented approximately 34.0% of market revenue in 2025, equivalent to about USD 1.41 billion, and is forecast to reach approximately USD 2.45 billion by 2032, expanding at an estimated 8.2% CAGR. Growth is being supported by increased adoption in fetal assessment, specialist women’s-health imaging and equipment upgrades.

Doppler ultrasound accounted for approximately 22.0% of the market in 2025, valued at around USD 0.91 billion. The segment is projected to grow at approximately 7.9% CAGR to reach about USD 1.55 billion by 2032, supported by maternal and fetal blood-flow assessment and higher-risk pregnancy monitoring.

 

By Portability

Cart-based systems dominated the market with approximately 73.0% share in 2025, representing around USD 3.03 billion. Hospitals, maternal-fetal-medicine centers and fertility clinics remain major users because complex examinations and high patient volumes favor full-size platforms. The segment is forecast to expand at approximately 5.85% CAGR, reaching about USD 4.51 billion by 2032.

The handheld ultrasound segment represented approximately 27.0% of market revenue in 2025, or around USD 1.12 billion, and is expected to grow substantially faster at approximately 10.4% CAGR. Revenue is projected to reach around USD 2.24 billion by 2032 as adoption expands across outpatient clinics, bedside imaging, smaller practices and decentralized healthcare settings.

By Application

Obstetrics was the largest application segment with approximately 66.0% of market revenue in 2025, equivalent to around USD 2.74 billion. Pregnancy generates recurring imaging requirements across prenatal assessment, fetal development monitoring and higher-risk pregnancies. The segment is projected to grow at approximately 6.6% CAGR and reach about USD 4.28 billion by 2032.

Gynecology represented approximately 34.0% of market revenue in 2025, valued at around USD 1.41 billion, and is forecast to grow faster at approximately 8.3% CAGR, reaching USD 2.47 billion by 2032. Demand is supported by large patient populations affected by fibroids, endometriosis, PCOS, ovarian cysts and other pelvic disorders requiring diagnostic or follow-up imaging.

 

By End User

Hospitals dominated the end-user segment with approximately 49.0% market share in 2025, representing around USD 2.03 billion. Their position reflects maternity services, emergency obstetric care, specialist gynecology departments and maternal-fetal-medicine capabilities. Hospital revenue is projected to reach approximately USD 3.14 billion by 2032, growing at around 6.4% CAGR.

Clinics accounted for approximately 25.0% of market revenue in 2025, or about USD 1.04 billion, and are forecast to reach around USD 1.67 billion by 2032 at a 7.0% CAGR. Greater availability of compact and handheld systems is supporting adoption across independent OB/GYN practices and outpatient centers.

Fertility centers represented approximately 18.0% of the market in 2025, valued at around USD 0.75 billion, and are projected to be the fastest-growing end-user segment at approximately 9.4% CAGR, reaching around USD 1.40 billion by 2032. Repeated follicular monitoring and ART-related imaging create higher examination frequency within this setting.

Ambulatory surgical centers accounted for approximately 8.0% of the market in 2025, representing around USD 0.33 billion, and are projected to reach approximately USD 0.54 billion by 2032 at a 7.3% CAGR.

 

By Geography

North America held the largest regional share at approximately 37.0% in 2025, representing around USD 1.54 billion. The market is projected to reach approximately USD 2.34 billion by 2032, expanding at around 6.2% CAGR. Established hospital infrastructure, fertility treatment activity, specialist maternal-fetal care and equipment replacement support regional demand.

Europe accounted for approximately 26.0% of the global market in 2025, valued at around USD 1.08 billion, and is forecast to reach approximately USD 1.70 billion by 2032 at a 6.7% CAGR. Replacement of older platforms, automation and specialist women’s-health imaging remain important sources of spending.

Asia-Pacific represented approximately 28.0% of market revenue in 2025, equivalent to around USD 1.16 billion, and is projected to be the fastest-growing major region at approximately 8.7% CAGR. The market is forecast to reach around USD 2.08 billion by 2032, supported by expanding maternity services, private healthcare investment and wider diagnostic access.

Latin America accounted for approximately 5.0% of the market in 2025, or around USD 0.21 billion, and is expected to reach approximately USD 0.34 billion by 2032 at a 7.3% CAGR. The Middle East & Africa represented approximately 4.0%, valued at around USD 0.17 billion, and is projected to reach approximately USD 0.29 billion by 2032 at an 8.2% CAGR, supported by expansion of maternal healthcare and portable diagnostic imaging.

 

Competitive Landscape and Market Direction

The Obstetrics & Gynecology Ultrasound Devices Market includes established companies such as GE HealthCare, Samsung Medison, Royal Philips, Siemens Healthineers, Canon Medical Systems and Mindray. Competition is increasingly centered on women’s-health specialization, automated measurements, workflow speed, software capabilities and portability.

GE HealthCare's updated Voluson systems, Samsung Medison's HERA Z20, Siemens' automated obstetric and fertility tools and Philips' handheld OB/GYN platforms reflect current investment priorities. Manufacturers are extending ultrasound systems beyond routine fetal imaging into fertility assessment, pelvic-floor imaging, fibroids, endometriosis and other gynecologic applications.

Segment revenue estimates indicate that 3D & 4D ultrasound, handheld systems, gynecologic applications, fertility centers and Asia-Pacific are positioned to grow faster than the overall market through 2032. At the same time, 2D ultrasound, cart-based systems, obstetrics, hospitals and North America are expected to retain the largest revenue positions within their respective categories.

Pregnancy will remain the largest recurring clinical foundation, but market expansion is becoming less dependent on birth growth alone. Higher-risk pregnancy monitoring, fertility services, common gynecologic disorders, equipment replacement and portable imaging are increasing the range of revenue opportunities. Automation adds another layer of growth by helping healthcare providers improve examination throughput and measurement consistency.

 

Obstetrics & Gynecology Ultrasound Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.15 Billion
Revenue Forecast in 2032	USD 6.75 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Technology, By Portability, By Application, By End-User, By Geography
By Technology	2D Ultrasound, 3D & 4D Ultrasound, Doppler Ultrasound
By Portability	Cart-Based, Handheld
By Application	Obstetrics, Gynecology
By End-User	Hospitals, Clinics, Fertility Centers, ASCs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prenatal screening and maternal healthcare utilization, wider adoption of 3D & 4D ultrasound for fetal assessment, expanding fertility treatment and reproductive medicine services, and growing demand for portable ultrasound systems across outpatient and point-of-care settings
Customization Option	Available upon request